Zentalis Pharmaceuticals, Inc. fell 11.1% on Thursday, November 12, 2026, on 1,625,000 shares. No headline about ZNTL came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Zentalis Pharmaceuticals, Inc. (ZNTL:NASDAQ) closed at $1.70 on November 13, 2026, up 1.19% on the day. The stock trades 75.5% below its 52-week high of $6.95 and 32.8% above its 52-week low of $1.28. Over the past year, it gained 27.8%. Zentalis Pharmaceuticals, Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, ZNTL closed higher on 115 days (46%). Its best day was April 9, 2026 (+60.14%) and its worst was March 27, 2026 (-21.35%). The stock moved 10% or more in a single session 26 times. It opened at least 5% above the previous day's high 1 time.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company's product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.
Find more stocks like ZNTL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.